title: A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
abstract: With advanced non-small-cell lung cancer (NSCLC) harboring, the anaplastic lymphoma kinase (ALK) gene rearrangement often responds impressively to ALK inhibitors, such as crizotinib. Acquired tumor resistance to ALK inhibition develops after a median progression-free survival of 7.7 to 10.9 months, with several mechanisms of resistance already described. Second generation ALK inhibitors, such as ceritinib, may overcome some of these mechanisms and have known efficacy in brain metastases. Their effect on intramedullary spinal cord metastases, a rare form of central nervous system metastases, is unknown.
authors.affiliation: Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
authors.forename: Josette
authors.initials: J
authors.lastname: Biya
authors.forename: Caroline
authors.initials: C
authors.lastname: Caramella
authors.forename: Colin R
authors.initials: CR
authors.lastname: Lindsay
authors.forename: David
authors.initials: D
authors.lastname: Planchard
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D013450:Sulfones / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013450:Sulfones; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib